A Phase 3 interventional study of GSK 1437173A and Placebo in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 24th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 10th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 4 started in 2013.
This study's enrollment of 237 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 27th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 3, and was the 18th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.
The study will be randomised into two groups based on the vaccination schedule in relation to the start of a chemotherapy cycle:
The protocol summary has been updated following Protocol Amendment 2, August 2014, leading to the increase of the enrolment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study:
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of vaccination. Acute disease is defined as the presence of a moderate or severe illness with or without fever, but excludes the underlying , as well as the expected symptoms/signs associated with that disease or its treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
Biological: GSK 1437173A
Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
Drug: Placebo
2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Also known as: HZ/su, GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine
2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups
Adjusted geometric means (GMC) of GSK1437173A over placebo for anti-glycoprotein E (gE) antibody enzyme-linked immunosorbent assay (ELISA) concentrations in PreChemo Groups only.
Time frame: At Month 2
Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations
Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.
Time frame: At Month 2
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Days With Solicited Local Symptoms
The number of days with any local symptoms has been assessed during the post-vaccination period.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal \[symptoms included nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Days With Solicited General Symptoms
The number of days with any general symptoms has been assessed during the post-vaccination period.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE= SAE assessed by the investigator as causally related to the study vaccination.
Time frame: From first dose up to 30 days post last vaccination
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.
Time frame: From first vaccination up to 30 days post last vaccination
Anti-VZV gE Antibody Concentrations
Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.
Time frame: At Months 0, 1, 6 and 13
Number of Subjects With Vaccine Responses for Anti-gE Antibody ELISA Concentrations
Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Time frame: At Months 1, 2, 6 and 13
Descriptive Statistics of the Frequency of gE-specific CD4[2+] T-cells in PreChemo Groups
Descriptive statistics were tabulated for CD4\[2+\] cells, which are gE specific CD4+ T-cells with at least two activation markers (\[2+\]), expressed from the activation markers interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40-ligand (CD40-L), as determined by intracellular cytokine staining (ICS) method.
Time frame: At Months 0, 1, 2 and 13
Number of Subjects With Vaccine Responses for gE-specific CD4[2+] T-cells in PreChemo Groups
Vaccine response defined as: For initially seronegative subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x320 Events/10E6 CD4+ T cells); For initially seropositive subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.
Time frame: At Months 1, 2 and 13
Number of Subjects With Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as causally related to the study vaccination.
Time frame: From 30 days post last vaccination up to study end (Month 13)
Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From 30 days post last vaccination up to study end (Month 13)
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 117 | 115 |
| Completed | 90 | 90 |
| Not completed | 27 | 25 |
| Withdrew: Serious adverse event | 13 | 12 |
| Withdrew: Withdrawal by subject | 12 | 9 |
| Withdrew: Migrated/moved from study area | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Other | 0 | 2 |
Adjusted geometric means (GMC) of GSK1437173A over placebo for anti-glycoprotein E (gE) antibody enzyme-linked immunosorbent assay (ELISA) concentrations in PreChemo Groups only.
| EL.U/mL | GSK1437173A-PreChemo | Placeb-PreChemo |
|---|---|---|
| Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups | 24501.57 (19051.99 to 31509.94) | 1056.77 (990.37 to 1127.62) |
Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations | 18291.7 (14432.1 to 23183.5) | 1060.5 (873.9 to 1287.1) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 83 | 2 |
| Grade 3 Pain, Dose 1 | 8 | 0 |
| Any Redness, Dose 1 | 33 | 0 |
| Grade 3 Redness, Dose 1 | 2 | 0 |
| Any Swelling, Dose 1 | 15 | 1 |
| Grade 3 Swelling, Dose 1 | 0 | 0 |
| Any Pain, Dose 2 | 52 | 5 |
| Grade 3 Pain, Dose 2 | 4 | 0 |
| Any Redness, Dose 2 | 20 | 0 |
| Grade 3 Redness, Dose 2 | 0 | 0 |
| Any Swelling, Dose 2 | 8 | 0 |
| Grade 3 Swelling, Dose 2 | 0 | 0 |
| Any Pain, Across doses | 90 | 7 |
| Grade 3 Pain, Across doses | 11 | 0 |
| Any Redness, Across doses | 40 | 0 |
| Grade 3 Redness, Across doses | 2 | 0 |
| Any Swelling, Across doses | 18 | 1 |
| Grade 3 Swelling, Across doses | 0 | 0 |
The number of days with any local symptoms has been assessed during the post-vaccination period.
| Days | GSK1437173A Group | Placebo Group |
|---|---|---|
| Pain, Dose 1 | 2.0 (2.0 to 4.0) | 2.0 (1.0 to 3.0) |
| Pain, Dose 2 | 2.0 (1.0 to 3.5) | 1.0 (1.0 to 2.0) |
| Redness, Dose 1 | 3.0 (2.0 to 5.0) | — |
| Redness, Dose 2 | 4.0 (2.0 to 5.0) | — |
| Swelling, Dose 1 | 4.0 (2.0 to 5.0) | 7.0 (7.0 to 7.0) |
| Swelling, Dose 2 | 3.5 (2 to 5.5) | — |
Assessed solicited general symptoms were fatigue, gastrointestinal \[symptoms included nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Fatigue, Dose 1 | 56 | 44 |
| Grade 3 Fatigue, Dose 1 | 10 | 3 |
| Related Fatigue, Dose 1 | 15 | 10 |
| Any Gastrointestinal, Dose 1 | 32 | 21 |
| Grade 3 Gastrointestinal, Dose 1 | 2 | 5 |
| Related Gastrointestinal, Dose 1 | 9 | 2 |
| Any Headache, Dose 1 | 28 | 24 |
| Grade 3 Headache, Dose 1 | 3 | 1 |
| Related Headache, Dose 1 | 10 | 4 |
| Any Myalgia, Dose 1 | 50 | 17 |
| Grade 3 Myalgia, Dose 1 | 8 | 3 |
| Related Myalgia, Dose 1 | 25 | 3 |
| Any Shivering, Dose 1 | 27 | 13 |
| Grade 3 Shivering, Dose 1 | 5 | 2 |
| Related Shivering, Dose 1 | 12 | 4 |
| Any Fever, Dose 1 | 13 | 4 |
| Grade 3 Fever, Dose 1 | 0 | 0 |
| Related Fever, Dose 1 | 11 | 1 |
| Any Fatigue, Dose 2 | 57 | 57 |
| Grade 3 Fatigue, Dose 2 | 9 | 6 |
| Related Fatigue, Dose 2 | 6 | 8 |
| Any Gastrointestinal, Dose 2 | 41 | 39 |
| Grade 3 Gastrointestinal, Dose 2 | 5 | 3 |
| Related Gastrointestinal, Dose 2 | 6 | 2 |
| Any Headache, Dose 2 | 29 | 25 |
| Grade 3 Headache, Dose 2 | 3 | 2 |
| Related Headache, Dose 2 | 7 | 2 |
| Any Myalgia, Dose 2 | 32 | 23 |
| Grade 3 Myalgia, Dose 2 | 4 | 1 |
| Related Myalgia, Dose 2 | 13 | 4 |
| Any Shivering, Dose 2 | 20 | 17 |
| Grade 3 Shivering, Dose 2 | 3 | 1 |
| Related Shivering, Dose 2 | 6 | 4 |
| Any Fever, Dose 2 | 8 | 1 |
| Grade 3 Fever, Dose 2 | 0 | 0 |
| Related Fever, Dose 2 | 4 | 0 |
| Any Fatigue, Across doses | 78 | 68 |
| Grade 3 Fatigue, Across doses | 16 | 8 |
| Related Fatigue, Across doses | 19 | 14 |
| Any Gastrointestinal, Across doses | 51 | 49 |
| Grade 3 Gastrointestinal, Across doses | 6 | 7 |
| Related Gastrointestinal, Across doses | 11 | 3 |
| Any Headache, Across doses | 43 | 40 |
| Grade 3 Headache, Across doses | 6 | 3 |
| Related Headache, Across doses | 16 | 6 |
| Any Myalgia, Across doses | 60 | 31 |
| Grade 3 Myalgia, Across doses | 12 | 4 |
| Related Myalgia, Across doses | 30 | 5 |
| Any Shivering, Across doses | 39 | 25 |
| Grade 3 Shivering, Across doses | 6 | 3 |
| Related Shivering, Across doses | 16 | 5 |
| Any Temperature, Across doses | 20 | 5 |
| Grade 3 Temperature, Across doses | 0 | 0 |
| Related Temperature, Across doses | 14 | 1 |
The number of days with any general symptoms has been assessed during the post-vaccination period.
| Days | GSK1437173A Group | Placebo Group |
|---|---|---|
| Fatigue, Dose 1 | 3.0 (1.5 to 6.0) | 5.0 (2.0 to 6.0) |
| Fatigue, Dose 2 | 5.0 (2.0 to 7.0) | 5.0 (3.0 to 7.0) |
| Gastrointestinal symptoms, Dose 1 | 2.5 (1.5 to 4.0) | 4.0 (2.0 to 6.0) |
| Gastrointestinal symptoms, Dose 2 | 4.0 (3.0 to 7.0) | 3.0 (2.0 to 7.0) |
| Headache, Dose 1 | 2.0 (1.0 to 3.5) | 2.0 (1.5 to 4.5) |
| Headache, Dose 2 | 2.0 (2.0 to 6.0) | 2.0 (1.0 to 5.0) |
| Myalgia, Dose 1 | 2.5 (1.0 to 4.0) | 2.0 (2.0 to 6.0) |
| Myalgia, Dose 2 | 3.0 (2.0 to 5.5) | 5.0 (3.0 to 7.0) |
| Shivering, Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 2.0) |
| Shivering, Dose 2 | 3.0 (1.0 to 6.0) | 2.0 (1.0 to 4.0) |
| Temperature, Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 3.0) |
| Temperature, Dose 2 | 1.5 (1.0 to 2.5) | 1.0 (1.0 to 1.0) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any AE(s) | 100 | 103 |
| Grade 3 AE(s) | 18 | 15 |
| Related AE(s) | 10 | 9 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE= SAE assessed by the investigator as causally related to the study vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any SAEs | 16 | 14 |
| Related SAEs | 0 | 0 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any pIMDs | 0 | 0 |
| Related pIMDs | 0 | 0 |
Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Anti-VZV gE, Month 0 | 1049.8 (865.8 to 1273.0) | 1116.7 (918.4 to 1358.0) |
| Anti-VZV gE, Month 1 | 24793.1 (18747.8 to 32787.6) | 1107.2 (920.0 to 1332.6) |
| Anti-VZV gE, Month 6 | 7730.4 (5358.4 to 11152.2) | 1380.2 (1066.3 to 1786.6) |
| Anti-VZV gE, Month 13 | 4477.3 (3482.4 to 5756.3) | 1064.7 (845.9 to 1340.1) |
Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Vaccine responders Month 1 | 73 | 0 |
| Vaccine responders Month 2 | 75 | 0 |
| Vaccine responders Month 6 | 31 | 1 |
| Vaccine responders Month 13 | 35 | 0 |
Descriptive statistics were tabulated for CD4\[2+\] cells, which are gE specific CD4+ T-cells with at least two activation markers (\[2+\]), expressed from the activation markers interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40-ligand (CD40-L), as determined by intracellular cytokine staining (ICS) method.
| CD4 T-cells/million T-cells | GSK1437173A-PreChemo | Placeb-PreChemo |
|---|---|---|
| CD4[2+] T-cells, Month 0 | 127.3 (49.7 to 192.4) | 104.8 (27.5 to 151.5) |
| CD4[2+] T-cells, Month 1 | 391.9 (139.7 to 603.7) | 50.0 (1.0 to 179.4) |
| CD4[2+] T-cells, Month 2 | 778.8 (393.1 to 1098.2) | 61.8 (17.4 to 139.5) |
| CD4[2+] T-cells, Month 13 | 332.9 (114.9 to 604.6) | 51.2 (1.0 to 288.6) |
Vaccine response defined as: For initially seronegative subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x320 Events/10E6 CD4+ T cells); For initially seropositive subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.
| Participants | GSK1437173A-PreChemo | Placeb-PreChemo |
|---|---|---|
| CD4[2+] T-cells, Month 1 | 5 | 0 |
| CD4[2+] T-cells, Month 2 | 11 | 0 |
| CD4[2+] T-cells, Month 13 | 3 | 0 |
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as causally related to the study vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any SAEs | 30 | 31 |
| Related SAEs | 0 | 0 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs) | 0 | 1 |
Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-vaccination period; SAEs: from first dose up to study end (Month 13).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 12/117 (10.3%) | 36/117 (30.8%) | 113/117 (96.6%) |
| Placebo Group | 11/115 (9.6%) | 42/115 (36.5%) | 103/115 (89.6%) |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/117 | 2/115 |
| NeutropeniaBlood and lymphatic system disorders | 2/117 | 4/115 |
| AnaemiaBlood and lymphatic system disorders | 2/117 | 3/115 |
| SepsisInfections and infestations | 3/117 | 2/115 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/117 | 2/115 |
| ConstipationGastrointestinal disorders | 0/117 | 2/115 |
| Neutropenic sepsisInfections and infestations | 1/117 | 2/115 |
| PneumoniaInfections and infestations | 1/117 | 2/115 |
| Acute kidney injuryRenal and urinary disorders | 1/117 | 2/115 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/117 | 2/115 |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PainGeneral disorders | 90/117 | 7/115 |
| FatigueGeneral disorders | 80/117 | 69/115 |
| MyalgiaMusculoskeletal and connective tissue disorders | 62/117 | 33/115 |
| Gastrointestinal disorderGastrointestinal disorders | 51/117 | 51/115 |
| HeadacheNervous system disorders | 45/117 | 41/115 |
| ErythemaSkin and subcutaneous tissue disorders | 43/117 | 1/115 |
| ChillsGeneral disorders | 39/117 | 25/115 |
| NauseaGastrointestinal disorders | 31/117 | 28/115 |
| AstheniaGeneral disorders | 30/117 | 28/115 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/117 | 23/115 |
| Age, Continuous(Years) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 57.1 ± 10.8 | 58.5 ± 11.7 | 57.79 ± 11.25 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Female | 70 | 69 | 139 |
| Male | 47 | 46 | 93 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Geographic ancestry — African Heritage/African American | 2 | 2 | 4 |
| Geographic ancestry — American Indian or Alaskan Native | 2 | 0 | 2 |
| Geographic ancestry — Asian - East Asian Heritage | 11 | 14 | 25 |
| Geographic ancestry — Asian - South East Asian Heritage | 0 | 2 | 2 |
| Geographic ancestry — White - Arabic/North African Heritage | 1 | 0 | 1 |
| Geographic ancestry — White - Caucasian/European Heritage | 92 | 88 | 180 |
| Geographic ancestry — Mixed Origin | 0 | 1 | 1 |
| Geographic ancestry — Missing | 9 | 8 | 17 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Mar 2013 to primary completion in Jun 2015, 27 months.
Results were first posted in Aug 2018, 3 years 1 month after primary completion. A results delay was requested in Nov 2015.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 27 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix